PARP Inhibitor competition heating up and it won't be dominated by one player for ovarian or br
"The PARP inhibitor market is going to be split. The question is to what extent, and whether insurers, pharmacy benefit managers and...
CRI's Comprehensive Analysis of clinical immune-oncology
Cancer Research Institute publishes analysis in Annals of Oncology 2017 "Advances in immuno-oncology (IO) are revolutionizing the...
Oncology New Drug Approvals in 2017
Oncology Drugs Approved in 2017 thru Dec 8th Aliqopa (copanlisib); Bayer; For the treatment of follicular lymphoma , Approved September...